TTK Healthcare’s seven-year audit record is unqualified and the company has never defaulted on borrowings or reported a cash loss. Two things cut against that stability: operating cash flow has swung deeply negative even as dividends continue at ₹10 per share, and reported profit leans on a recurring series of exceptional items, including a fresh labour-code charge and a GST refund booked before receipt.
Key findings
- Operating cash flow turns deeply negative while dividends hold at ₹10 per share
Major- Standalone net cash used in operations widened to ₹(21.15) crore in FY2025-26 from ₹(3.98) crore in FY2024-25, even as reported profit after tax stood at ₹65.68 crore. The Board recommended a final dividend of ₹10 per share for the third consecutive year, requiring a cash outflow of roughly ₹14.13 crore each time. - Exceptional items repeatedly reshape profit, with a ₹7.58 crore labour-code charge and a ₹3.5 crore GST refund
Major- A net exceptional charge of ₹7.58 crore was recognised in FY2025-26 for the incremental impact of four Labour Codes notified on 21 November 2025, while a ₹3.5 crore GST refund was taken as exceptional income because the right to receive had crystallised and recovery was virtually certain under Ind AS 10, though sanction came after the reporting date. This follows a pattern: a ₹19.77 crore property-sale gain and a ₹5.86 crore inventory write-off in FY2024-25, a ₹2.49 crore land-sale gain in FY2021-22, and ₹8.09 crore of tax-refund interest treated as exceptional income in FY2020-21. - Income-tax demands exceed ₹9 crore and a Supreme Court pricing case carries an unquantified exposure
Minor- Five separate income-tax disputes concerning withdrawal of interest under Section 244A and charging of interest under Section 234D for assessment years 2013-14 to 2017-18 carry a total expected financial implication of ₹9,12,86,331, disclosed between February and August 2025. Separately, both TTK Healthcare and the Government of India have filed Special Leave Petitions before the Supreme Court on whether ceiling prices under DPCO 2013 can be fixed for condoms; the company states the financial impact is not quantifiable and has made no provision. - Promoter control is entrenched and public institutional shareholders have opposed key resolutions including the failed delisting
Minor- Mr T T Raghunathan has served as Executive Vice Chairman or Executive Chairman continuously since 1 November 2001, and the board proposes his reappointment for a further five years to 31 October 2031, notwithstanding he attained age 70 on 8 July 2022. His total remuneration was exactly ₹1,19,00,000 in each of the five years through FY2025-26, while public institutional shareholders voted 41.65% against the 2023 delisting proposal and 99.01% against the appointment of an Independent Director at the July 2024 AGM. Promoter shareholding has remained at 74.56% with zero pledge. - Audit opinions are unqualified across seven years, but a database-level audit-trail exception has persisted since FY2023-24
Minor- The statutory auditor issued an unqualified opinion on standalone financial statements and internal financial controls for every year from FY2019-20 through FY2025-26. However, the accounting software’s audit trail was not enabled to log direct data changes at the database level in FY2023-24, FY2024-25, and FY2025-26, though the transaction-level edit log operated throughout with no tampering found.
What to watch
- Executive Chairman reappointment. The AGM notice dated 27 June 2026 seeks approval for Mr T T Raghunathan’s reappointment for five years from 1 November 2026; his current term expires 31 October 2026.
- DPCO Supreme Court outcome. The Special Leave Petitions before the Supreme Court on condom ceiling prices remain unresolved, with no provision made as of the FY2025-26 annual report.
- Income-tax appeals. Resolution of the ₹9.13 crore in disputed demands for AYs 2013-14 to 2017-18, disclosed between February and August 2025.
- Audit-trail remediation. Whether the database-level audit-trail exception, present from FY2023-24 through FY2025-26, is resolved in the next audit cycle.
Bottom line: This is a disclosed, consistently audited record with no default or going-concern doubt. The character of the risk is a growing gap between reported profit and the cash that reaches the balance sheet, alongside a profit bridge that depends on exceptional items year after year. Watch whether the cash-flow divergence narrows and whether the labour-code provision and GST refund treatment survive the next audit cycle.